Status:

RECRUITING

Prognosis Stratification for Advanced HCC Receiving TACE with PD-1/PD-L1 Inhibitors and Molecular Target Therapies

Lead Sponsor:

Zhongda Hospital

Conditions:

Hepatocellular Carcinoma

Eligibility:

All Genders

18+ years

Brief Summary

The purpose of this study is to establish a personalized model of prognosis stratification for patients with advanced-stage hepatocellular carcinoma (HCC) receiving transarterial chemoembolization (TA...

Detailed Description

In patients with advanced-stage hepatocellular carcinoma (HCC), previous studies showed that transarterial chemoembolization (TACE) in combination with immune checkpoint inhibitors (ICIs) and molecula...

Eligibility Criteria

Inclusion

  • Has a diagnosis of HCC confirmed by radiology, histology, or cytology;
  • Barcelona Clinic Liver Cancer (BCLC) stage C with the presence of extrahepatic spread and/or macrovascular invasion;
  • Has not received any previous systemic therapy for HCC (including chemotherapy, molecularly targeted therapy, immunotherapy);
  • Both PD-1/PD-L1 inhibitors and anti-angiogenesis drugs patients received only include marketed drugs but are not limited to HCC approval;
  • TACE was performed after the first PD-1/PD-L1 inhibitor/anti-angiogenic drug treatment or before treatment (within 3 months);
  • Received at least 1 cycle of PD-1/PD-L1 inhibitor/anti-angiogenic drug combination therapy after TACE treatment;
  • Has repeated measurable intrahepatic lesions;

Exclusion

  • Cholangiocarcinoma, fibrolamellar, sarcomatoid hepatocellular carcinoma, and mixed hepatocellular/cholangiocarcinoma subtypes(confirmed by histology, or pathology) are not eligible;
  • Unable to meet criteria of combination timeframe described above;
  • Child-Pugh C or PS\>2 or Severe hepatic encephalopathy

Key Trial Info

Start Date :

June 1 2024

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

March 1 2025

Estimated Enrollment :

950 Patients enrolled

Trial Details

Trial ID

NCT06607120

Start Date

June 1 2024

End Date

March 1 2025

Last Update

September 23 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Zhongda Hospital

Nanjing, Jiangsu, China

Prognosis Stratification for Advanced HCC Receiving TACE with PD-1/PD-L1 Inhibitors and Molecular Target Therapies | DecenTrialz